DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the Phaarmasia Ltd (PHRMASI) share price today?

Phaarmasia Ltd (PHRMASI) is trading at ₹89.61 on the BSE, down 4.99% on the day. Source: DocStoX.

What is the PE ratio of Phaarmasia Ltd?

Phaarmasia Ltd has a price-to-earnings (PE) ratio of 3.7 in the Healthcare sector.

What is the market capitalisation of Phaarmasia Ltd?

Phaarmasia Ltd has a market capitalisation of approximately ₹64 crore.

Phaarmasia Ltd

PHRMASI·BSE·Healthcare

₹89.61▼ -4.71 (-4.99%)

Healthcare · Pharmaceuticals & Biotechnology

A steady, established business

Day₹89.61

₹94.60

52W₹26

₹13260%

Open

₹94.60

High

₹94.60

Low

₹89.61

Prev Close

₹94.32

Volume

VWAP

₹90.31

Snapshot

Key fundamentals

Market Cap

₹64 Cr

P/E Ratio

3.70Cheap

P/B Ratio

3.61

EPS

₹24.22

Book Value

₹26.15

ROE

-18.19%Weak

ROCE

-16.00%Weak

Dividend Yield

0.00%

Debt / Equity

0.05Low

Face Value

₹10.00

52W High

₹131.75

52W Low

₹26.00

Sector

Healthcare

Industry

Pharmaceuticals & Biotechnology

Avoid

None moatHigh uncertainty

Fair value estimate

₹14

▼ 84.2%downside

Trading at ₹90 — 84% above our estimate

BearFair valueBull

₹4₹14₹17

/100

Business quality — Watch the fundamentals

Growth 50Profitability 0Efficiency 0Valuation 99

Plain English

Our view

A steady, established business
Virtually debt-free balance sheet
Weak returns on equity (-18%)

Strengths

Virtually debt-free balance sheet
Reasonably priced at 4× earnings
Promoters hold a controlling stake

Risks

Weak returns on equity (-18%)

How we got there

Fair value methods

Residual income

-18% ROE fading to 12% over ~3 yrs, on ₹26 book

₹17

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹4

Analyst target

No analyst coverage

—

Blended fair value₹14

What the numbers say

Investment thesis

Bull case

Virtually debt-free balance sheet
Reasonably priced at 4× earnings
Promoters hold a controlling stake

Bear case

Weak returns on equity (-18%)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

3.7Cheap

Below 15× is value territory; above 35× prices in strong growth

ROE

-18.2%Weak

Above 15% is considered healthy for Indian equities

ROCE

-16.0%Weak

Above 18% means capital is working hard

Debt/Eq

0.05Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹64 Cr

P/B

3.61

EPS

₹24.22

Div Yield

—

What changed

Recent changes

No notable changes to report.

What matters

News impact

Overview

Valuation

Attractive

P/E 3.7×

Growth

Strong

+20% rev CAGR

Profitability

Loss-making

-18.2% ROE

Financial health

Rock solid

D/E 0.05

Momentum

N/A

No technicals

Today

Trading activity

Delivery %—

Turnover₹1,174 Cr

Trades3

VWAP₹90.31

Face value₹10.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+20.5%

+24.2%

10Y

+12.9%

Profit

—

10Y

—

EPS

—

-41.8%

10Y

-6.7%

Profile

Pros

Company is almost debt free.
Company is expected to give good quarter
Company has delivered good profit growth of 44.8% CAGR over last 5 years
Debtor days have improved from 60.8 to 39.7 days.

Watch-outs

Cons

Stock is trading at 2.91 times its book value
Company has a low return on equity of -0.39% over last 3 years.
Earnings include an other income of Rs.20.0 Cr.
Working capital days have increased from -17.3 days to 62.1 days

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Ownership was broadly stable versus the previous quarter. The QoQ column shows each group's change versus the prior quarter.

74%

Promoter

Promoters

73.5%0.00

Public

25.7%-0.15

FII / FPI

0.0%0.00

DII

0.1%+0.01

Others

0.8%

Total shareholders

20,301-103 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter73.51%

DII0.06%

Public25.66%

Others0.77%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

Incorporated in 1981, Phaarmasia Ltd is engaged in manufacturing and marketing of Cosmetics, Oral Contraceptive Pills (OCP) and Combipack with Iron Tablets

Phaarmasia Ltd valuation & research

Deep-dive tools with DocStoX's fair-value estimate, ratios and peers.

Fair Value Intrinsic Value DCF Valuation Financial Ratios Peers

Phaarmasia Ltd peers in Healthcare

Other Healthcare stocks on the NSE & BSE. See the full Healthcare sector list.

Sun Pharmaceutical Industries Ltd Divis Laboratories Ltd Torrent Pharmaceuticals Ltd Apollo Hospitals Enterprise Ltd Zydus Lifesciences Ltd Cipla Ltd Lupin Ltd Max Healthcare Institute Ltd Mankind Pharma Ltd Dr Reddys Laboratories Ltd Aurobindo Pharma Ltd Laurus Labs Ltd

Compare Phaarmasia Ltd with peers

Phaarmasia Ltd vs Sun Pharmaceutical Industries Ltd Phaarmasia Ltd vs Divis Laboratories Ltd Phaarmasia Ltd vs Torrent Pharmaceuticals Ltd Phaarmasia Ltd vs Apollo Hospitals Enterprise Ltd Phaarmasia Ltd vs Zydus Lifesciences Ltd Phaarmasia Ltd vs Cipla Ltd

Related tools & concepts

Value Phaarmasia Ltd with the ratios and calculators DocStoX uses in its analysis.

P/E RatioPrice to earnings Return on Equity (ROE)Profitability ROCECapital efficiency Debt to EquityLeverage P/B RatioPrice to book Net Profit MarginBottom-line efficiency DCF / Intrinsic ValueEstimate fair value CAGR CalculatorAnnualised return Dividend YieldIncome on price Position SizeRisk-based sizing Brokerage CalculatorCharges on a trade SIP CalculatorSystematic investing

Phaarmasia Ltd

Key fundamentals

Key statistics

Recent changes

News impact

Overview

Trading activity

Technical signals

Growth (CAGR)

Company information

Pros

Cons

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership breakdown

Ownership over time

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Frequently asked questions

Phaarmasia Ltd valuation & research

Phaarmasia Ltd peers in Healthcare

Compare Phaarmasia Ltd with peers

Related tools & concepts

Key statistics

Recent changes

News impact

Trading activity

Technical signals

Growth (CAGR)

Company information

Pros

Cons

Ownership breakdown

Ownership over time

Frequently asked questions